SEC Form 4Coverage since Nov 10, 2025Open-market trades only
$ADPT insider trading
Over the last 12 months, Adaptive Biotechnologies insiders reported no purchases and 66 sales totaling $118.6M across SEC Form 4 filings. 80% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $118.6M 66 events
- Events · 12m
- 66 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 80% of events, not dollars
Side
Price · $ADPT · 3Mvia TradingView
Top insiders · 12m
RUBINSTEIN JULIEPresident and COO14× · $13.4M
LO FRANCISChief People Officer10× · $9.9M
ROBINS HARLAN SChief Scientific Officer10× · $29.6M
BOBULSKY SUSANChief Commercial Officer, MRD8× · $1.2M
ROBINS CHAD MCEO and Chairman8× · $39.8M
All insider trades
50 of 66 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | OWEN KATEY EINTERZD | ▼ Sale | 9,615 | $26 | $250K | -10.9% | — |
| Aug 18, 2026 | HERSHBERG ROBERTD | ▼ Sale | 30,664 | $24.4 | $748K | -39.6% | 2 tranches |
| Aug 18, 2026 | ROBINS CHAD MCEO and Chairman · O·D | ▼ Sale | 600,000 | $24.8 | $14.9M | -21.6% | 4 tranches |
| Aug 17, 2026 | NEUPERT PETER MD | ▼ Sale | 124,690 | $25.15 | $3.1M | -48.8% | 3 tranches |
| Aug 10, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 3,000 | $25 | $75K | -0.8% | plan |
| Jul 30, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 1,299 | $24 | $31K | -0.3% | plan |
| Jul 21, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 492,400 | $21.89 | $10.8M | -37.7% | plan · 2 tranches |
| Jul 16, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 5,000 | $23 | $115K | -1.2% | plan |
| Jul 15, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 105,762 | $22.59 | $2.4M | -31.4% | plan |
| Jul 2, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 386,240 | $22.01 | $8.5M | -27.5% | plan · 2 tranches |
| Jul 2, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 95,842 | $22.51 | $2.2M | -29.3% | plan · 3 tranches |
| Jul 1, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 487 | $22 | $11K | -0.1% | plan |
| Jun 29, 2026 | BENZENO SHARONChief Commercial Ofc Imm Med · O | ▼ Sale | 165,802 | $21.13 | $3.5M | -42.8% | plan · 2 tranches |
| Jun 25, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 5,000 | $20.5 | $103K | -1.2% | plan |
| Jun 25, 2026 | GRIFFIN MICHELLE RENEED | ▼ Sale | 52,084 | $20.18 | $1.1M | -76.9% | plan |
| Jun 16, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 106,160 | $17.41 | $1.8M | -7% | plan · 2 tranches |
| Jun 11, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 5,000 | $19 | $95K | -1.2% | plan |
| Jun 4, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 39,741 | $17.49 | $695K | -13.7% | plan |
| Jun 4, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 11,000 | $18 | $198K | -2.6% | plan |
| Apr 27, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 19,037 | $14.23 | $271K | -4.8% | plan |
| Apr 24, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $13.96 | $798K | -13% | plan · 3 tranches |
| Apr 21, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 69,061 | $14.6 | $1.0M | -14.9% | plan · 3 tranches |
| Apr 16, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $14.45 | $826K | -12.3% | plan · 3 tranches |
| Apr 13, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $13.26 | $758K | -12% | plan · 6 tranches |
| Apr 8, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 10,000 | $14.85 | $149K | -0.7% | plan |
| Apr 8, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 22,564 | $15.07 | $340K | -7.7% | plan |
| Apr 8, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 69,061 | $14.34 | $991K | -13.7% | plan · 4 tranches |
| Apr 8, 2026 | ROBINS CHAD MCEO and Chairman · O·D | ▼ Sale | 120,595 | $14.65 | $1.8M | -5.2% | plan · 2 tranches |
| Apr 2, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 38,120 | $14.52 | $554K | -7.9% | plan · 2 tranches |
| Mar 31, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $13.14 | $751K | -11.1% | plan · 4 tranches |
| Mar 26, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $14.03 | $802K | -10.9% | plan · 3 tranches |
| Mar 23, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $13.46 | $770K | -10.6% | plan · 3 tranches |
| Mar 18, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 57,180 | $13.33 | $762K | -10.4% | plan · 3 tranches |
| Mar 13, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 179,703 | $13.21 | $2.4M | -26.1% | plan · 5 tranches |
| Mar 11, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 41,338 | $13.17 | $544K | -8.8% | — |
| Mar 11, 2026 | BENZENO SHARONChief Commercial Ofc Imm Med · O | ▼ Sale | 63,103 | $13.17 | $831K | -18.8% | — |
| Mar 11, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 470,266 | $13.17 | $6.2M | -23.6% | 2 tranches |
| Mar 11, 2026 | PISKEL KYLEChief Financial Officer · O | ▼ Sale | 18,672 | $13.17 | $246K | -6.7% | — |
| Mar 11, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 30,593 | $14.08 | $431K | -9.5% | plan |
| Mar 11, 2026 | ROBINS CHAD MCEO and Chairman · O·D | ▼ Sale | 470,167 | $13.17 | $6.2M | -17% | 2 tranches |
| Mar 11, 2026 | GRIFFIN MICHELLE RENEED | ▼ Sale | 15,394 | $13.91 | $214K | -49.6% | — |
| Mar 10, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 81,342 | $14.9 | $1.2M | -11.2% | plan · 3 tranches |
| Mar 5, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 38,074 | $15.09 | $575K | -10.6% | — |
| Mar 5, 2026 | RUBINSTEIN JULIEPresident and COO · O | ▼ Sale | 92,823 | $16.09 | $1.5M | -13.9% | plan · 4 tranches |
| Mar 3, 2026 | GRIFFIN MICHELLE RENEED | ▼ Sale | 48,044 | $15.3 | $735K | -75.7% | plan |
| Mar 3, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 24,233 | $16.19 | $392K | -2.1% | plan · 2 tranches |
| Mar 3, 2026 | ROBINS CHAD MCEO and Chairman · O·D | ▼ Sale | 524,998 | $15.85 | $8.3M | -21.3% | plan · 4 tranches |
| Feb 4, 2026 | PISKEL KYLEChief Financial Officer · O | ▼ Sale | 2,145 | $18.46 | $40K | -1% | plan |
| Feb 3, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 42,788 | $18.68 | $799K | -3.5% | plan · 2 tranches |
| Feb 2, 2026 | ROBINS CHAD MCEO and Chairman · O·D | ▼ Sale | 124,998 | $18.44 | $2.3M | -4.8% | plan |
Every $ADPT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Adaptive Biotechnologies filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ADPT feed.